Plain language summaries of clinical study results are intended to share the findings of clinical research with study participants, patients, and the public in easy-to-understand language. UCB currently posts these summaries for Phase 1 to 4 clinical trials after the product and indication are authorized for marketing.Plain language summaries are also included with other study information via the Compounds drop-down menu on the Clinical Studies Index page. Bimekizumab AS0010 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis AS0011 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis HS0003 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa HS0004 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa PA0010 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis PA0011 - A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis. PS0008 - Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis PS0009 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis PS0013 - A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque PS0014 - A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis PS0015 - A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis PS0020 - A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis PS0032 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis PS0041 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis UP0119 - An Open-Label, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants Brivaracetam EP0085 - An Open-Label, Multicenter, Follow-Up Study To Evaluate The Long-Term Safety And Efficacy Of Brivaracetam Used As Adjunctive Treatment In Subjects ≥16 Years Of Age With Partial Seizures With Or Without Secondary Generalization EP0132 - A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy EP0231 - A Multiple-Dose, Open-Label, Randomized, 2-Way Cross-Over Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Participants N01252 - Brivaracetam for the treatment of partial‑onset seizures (focal seizures) in people from 16 to 70 years old with epilepsy N01253 - Brivaracetam for the treatment of partial-onset seizures (focal seizures) in people from 16 to 70 years old with epilepsy N01266 - Open-label, single-arm, multicenter, long-term study to evaluate safety and efficacy of brivaracetam used as adjunctive treatment in pediatric subjects with epilepsy N01358 - Brivaracetam for the treatment of partial-onset seizures (focal seizures) in people from 16 to 80 years old with epilepsy Certolizumab pegol AKS001 - Certolizumab Pegol for the Treatment of Axial Spondyloarthritis in Adults C87014 - Certolizumab Pegol for the Treatment of Rheumatoid Arthritis in Adults C87027 - Certolizumab Pegol for the Treatment of Rheumatoid Arthritis in Adults C87031 - Certolizumab Pegol for the Treatment of Crohn’s Disease in Adults C87032 - Certolizumab Pegol for the Treatment of Crohn’s Disease in Adults C87050 - Certolizumab Pegol for the Treatment of Rheumatoid Arthritis in Adults C87077 - A study to learn if certolizumab pegol plus methotrexate works in participants who are already taking methotrexate PS0002 - A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis PS0003 - A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis PS0005 - A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis PSA001 - Certolizumab Pegol for the Treatment of Psoriatic Arthritis in Adults RA0043 - A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA) RA0044 - A study to learn if certolizumab pegol works in Chinese participants with active rheumatoid arthritis RA0055 - A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical response in the treatment of DMARD-naïve adults with early active rheumatoid arthritis RA0077 - Direct Comparison of Certolizumab Pegol versus Adalimumab in Rheumatoid Arthritis: 2-Year Efficacy and Safety Results from the Randomized EXXELERATE Study UP0016 - To look at the amount of certolizumab pegol in breast milk (CRADLE) UP0017 - To look at the transfer of certolizumab pegol across the placenta (CRIB) UP0085 - A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1b Study In Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia® (Certolizumab Pegol) Fenfluramine EP0215 - An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome ZX008-1501, ZX008-1502, ZX008-1504 - This is a summary of the main results of the 3 studies: ZX008-1501, ZX008-1502, ZX008-1504 - A study to learn how well fenfluramine works and how safe it is in children and young adults with Dravet syndrome ZX008-1601 (EP0214) - A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults with LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults with LGS Ginisortamab (UCB6114) ONC001 - A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors Lacosamide EP0008 - A study to learn if lacosamide helps control seizures in Chinese and Japanese participants with epilepsy who are taking their usual anti-seizure medicines EP0024 - A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Japanese Adults With Partial-onset Seizures With or Without Secondary Generalization EP0034 - A Multicenter, Open-label, Long-term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in pediatric Subjects With Epilepsy With Partial-Onset Seizures EP0151 - A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment SP667 - Lacosamide in Adults for the Treatment of Epileptic Partial Seizures SP754 - Lacosamide for the Treatment of Epileptic Partial Seizures in Adolescents (16 years and older) and Adults SP755 - Lacosamide for the Treatment of Epileptic Partial Seizures in Adolescents (16 years and older) and Adults SP902 - A historical-controlled, multicentre, double blind, randomized trial to assess the efficacy and safety of conversion to lacosamide 400mg/day monotherapy in subjects with partial onset seizures SP0969 - A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of lacosamide as adjunctive therapy in subjects with epilepsy ≥4 years to <17 years of age with partial-onset seizures SP0982 - A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy SP0993 - A multicenter, double-blind, double-dummy, randomized, positive controlled study comparing the efficacy and safety of lacosamide (200 to 600mg/day) to controlled release carbamazepine (400 to 1200mg/day), used as monotherapy in subjects (≥16 years) newly or recently diagnosed with epilepsy and experiencing partial onset or generalized tonic clonic seizures Levetiracetam N051 - Evaluation of the efficacy and tolerability of UCB L059 (500 and 1000 mg b.i.d., tablets) add-on treatment in refractory epileptic patients with partial onset seizures: a 32-week double-blind placebo-controlled crossover multicenter trial N132 - A study to learn if levetiracetam works in participants with epilepsy who are taking their usual anti-seizure medicines N138 - Evaluation of the efficacy and tolerability of ucb L059 (1500 mg b.i.d., 500 mg tablets) monotherapy in epileptic patients with complex partial onset seizures, having experienced improved seizure control under add-on treatment N159 - Evaluation of The Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial N165 - Bridging Study of L059 (Levetiracetam) in Patients with Epilepsy by Double Blind Method N01009 - A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age from 1 Month to Less Than 4 Years of Age N01057 - Levetiracetam for the Treatment of Generalised Epilepsy in Children and Adults N01061 - A study to learn if levetiracetam works when taken by itself in people with newly diagnosed epilepsy who have focal seizures or grand mal seizures N01102 - A Double-blind, Placebo-controlled, Randomized Study: 16-week Evaluation of the Efficacy and Safety of Levetiracetam (LEV) as Add-on Therapy in Adults and Adolescents Older than 16 Years Suffering from Partial Seizures N01103 - A 19-week, Randomized, Double-blind, Multicenter, Placebo controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20-60 mg/kg/d, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4-16 Years Old, Inclusive, with Partial Onset Seizures N01148 - A study to see if levetiracetam worked and to learn about its safety in children and teenagers 1 month and older with epilepsy N01159 - A double-blind, multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of adjunctive treatment with oral levetiracetam (L059) in epilepsy patients aged ≥16 with generalized tonic-clonic (GTC) seizures N01221 - A study to learn if levetiracetam works in Japanese participants with epilepsy who are taking their usual anti-seizure medicines N01274 - Levetiracetam for the Treatment of Epilepsy in Children (4 - 16 Years Old) N01275 - Levetiracetam for Treatment of Epilepsy in Children (1 Month Old to 4 Years Old) N01364 - A study to learn if levetiracetam works when taken by itself in Chinese participants with newly diagnosed epilepsy who have focal seizures N01375 - A study to learn how levetiracetam worked when taken by itself in Japanese participants with newly diagnosed epilepsy N01378 - An open-label, multicenter study to evaluate the safety of adjunctive treatment with intravenous levetiracetam (L059IV) in epilepsy patients aged ≥16 years with partial onset seizures Minzasolmin UP0073 - A 2-Part Study to Evaluate the Relative Bioavailability of 2 New Formulations of UCB0599 and the Effect of Esomeprazole on the PK of UCB0599 in Healthy Participants (Part A, Open-Label) and to Assess the Safety/Tolerability and PK of UCB0599 in Healthy Participants of Japanese and Chinese Origins (Part B, Double-Blind) UP0152 - An Open-Label, Randomized Study to Evaluate the Relative Bioavailability of a New Tablet Formulation of Minzasolmin and the Potential Effect of Food on the Pharmacokinetics of Minzasolmin in Healthy Participants Romosozumab 20070337 - A Multicenter, International, Randomized, Double-blind, Placebocontrolled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis 20110142 - A Multicenter, International, Randomized, Double-blind, Alendronatecontrolled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis 20110174 - A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis Rotigotine SP506 - Rotigotine in Adults for the Treatment of Early Parkinson’s Disease SP512 - Rotigotine in Adults for the Treatment of Early Parkinson’s Disease SP513 - Rotigotine in Adults for the Treatment of Early Parkinson’s Disease SP515 - Rotigotine for the Treatment of Advanced Parkinson’s Disease in Adults SP650 - Rotigotine in Adults for the Treatment of Advanced Parkinson’s Disease SP790 - Rotigotine for the Treatment of Restless Legs Syndrome in Adults SP792 - Rotigotine for the Treatment of Restless Legs Syndrome in Adults SP0914 - A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of the Rotigotine Transdermal Patch in Chinese Subjects with Early-Stage Idiopathic Parkinson’s Disease SP1037 - A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Rotigotine Transdermal Patch in Chinese Subjects with Advanced-stage, Idiopathic Parkinson’s Disease Who Are Not Well Controlled on Levodopa Rozanolixizumab AIE001 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis FM0001 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a, Proof-Of-Concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome MG0003 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis MG0007 - An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis MG0020 - An Open-label, Crossover Study to Evaluate Rozanolixizumab Self-administration by Study Participants With Generalized Myasthenia Gravis TP0003 - Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) TP0004 - An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia UP0106 - A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants Staccato Alprazolam UP0104 - An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study to Evaluate The Relative Bioavailability of Staccato Alprazolam Compared to Oral Alprazolam in Healthy Study Participants Zilucoplan DV0012 - An open-label, single center, randomized, 2-way crossover, singledose, bioequivalence study of zilucoplan injected subcutaneously either by prefilled syringe or an auto-injector in healthy adult participants DV0013 - A Multicenter, Open-Label, Outpatient Study to Evaluate the Safe And Effective Use of a Zilucoplan Auto-Injector Combination Product for Subcutaneous Self-Administration by Study Participants With Generalized Myasthenia Gravis MG0010 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis MG0017 - A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan
